Global Heparin Induced Thrombocytopenia Market - 2023-2030

Global Heparin Induced Thrombocytopenia Market - 2023-2030

Global Heparin-Induced Thrombocytopenia Market reached US$ 9.2 billion in 2022 and is expected to reach US$ 12.9 billion by 2030, growing with a CAGR of 4.4% during the forecast period 2023-2030.

Heparin-induced thrombocytopenia (HIT) is described as a drop in platelet count briefly after beginning heparin, which settles behind discontinuing heparin and has no further evident reason. The mild thrombocytopenia surfacing within four days of starting heparin is the result of an instantaneous effect of heparin on platelets. It is not immune cell-associated whereas occurs to be induced by a direct agglutinating consequence of heparin on platelets. It is not associated with thrombosis and subsides regardless of the heparin treatment continuation.

The severe thrombocytopenia, generally surfacing between four and 14 days after beginning heparin, is related to both arterial and venous thrombosis (HIT/T) and occurs to be immune-mediated. Immune HIT/T should be evaluated whenever the platelet count drops by 50% in an individual obtaining heparin. Even though it is generally related to intravenous infusion of unfractionated heparin, immune HIT/T has been informed in connection with subcutaneous low-dose heparin, heparin flushes, heparin-coated catheters, low molecular weight heparins, and heparinoids.

The growing use of heaprine for distinct diorder treatments, and growing cases of thrombocytopenia is expected to boost the global Heparin-induced thrombocytopenia market growth in the forecast period. Further, the growing research activities and with fundings investments in Heparin-Induced Thrombocytopenia are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Use of Heparin Treatment

Several thrombotic disorders require heparin treatment to decrease the threat of thrombosis. Additionally, the therapy has shown some success in decreasing the morbidity and mortality related to thrombotic conditions. Despite the observed success of the treatment, HIT has been a significant reason for morbidity, leading to amputations induced due to the heparin treatment. Further, none of the most current anticoagulants, whether oral or parenteral, merge heparin’s special pharmacologic characteristics, such as quick beginning of activity, capacity to impede multiple coagulant proteins, comfort of monitoring, and reversibility.

Including the favorable characteristics are expected to persist to uphold UFH and its derivatives, the low-molecular-weight heparins (LMWHs), at the therapeutic fore for several presentations where other treatments are presently lacking, for example, the (cardiac surgery), inappropriate (mechanical valves), or untested (cancer-associated thrombosis and antiphospholipid antibody syndrome). Therefore, as a drug type, the heparin family (UFH and LMWH) has the potential to stay in clinical usage for the foreseeable future, boosting the global Heparin-Induced Thrombocytopenia market growth during the forecast period.

Increasing Research Activities and Investments

The increasing research activities and funding are expected to boost the global heparin-induced thrombocytopenia market growth during the forecast period. For instance, in June 2023, Veralox Therapeutics, a clinical-stage biotechnology corporation designed a unique type of therapy targeting the 12-lipoxygenase (12-LOX) pathway to manage some of the treatment’s considerably constant and severe immune-mediated disorders. Also, Veralox obtained $24 million in funding to progress VLX-1005 via a Phase 2a proof-of-concept investigation assessing its influence on heparin-induced thrombocytopenia (HIT), a life-threatening infrequent condition induced by an aberrant immune response to heparin exposure.

Further, in November 2021, PlateletBio, a preclinical-stage biotechnology corporation taking a lead in an altogether unique platform of allogeneic cell treatments established on platelet biology, secured $75.5 million in Series B financing. The round encloses new investors SymBiosis, K2 HealthVentures, and Oxford Finance and participation from existing investors. The corporation intends to utilize the financing earnings to resume preclinical development of its top platelet-like cell (PLC) program as a novel treatment for Immune Thrombocytopenia (ITP), an autoimmune disorder, additionally design its remarkable engineered PLC (ePLC) platform and promote its proprietary manufacturing capacities.

High Treatment Cost

The high cost of HIT treatment is expected to hamper the global market growth during the forecast period owing to long treatment period with frequent drug doses over time. For instance, despite the availability of considerable non-heparin anticoagulants for the therapy of heparin-induced thrombocytopenia (HIT), little data is public comparing the cost-effectiveness of these treatments.

The analysis of argatroban, bivalirudin, and fondaparinux for the treatment of suspected HIT from the institutional perspective demonstrated that the institutional costs, fondaparinux prevailed over both argatroban and bivalirudin in terms of cost $151 vs. $1250 and $1466, respectively. The long duration of the treatment sums up to high treatment cost slowing the global market growth during the forecast period.

Treatment Side Effect

The large number of heparin-induced thrombocytopenia treatment side effects are expected to hamper the global heparin-induced thrombocyto penia market. For instance, the Argatroban (intravenous route) side effects include Bleeding from the bladder, hematuria, blurry eyesight, chest discomfort, disorder, dizziness, faintness, or postural lightheadedness, fever, no blood pressure or pulse stopping of heart, perspiring, fainting, distinctive fatigue or weakness among others.

Similarly, Fondaparinux (subcutaneous route) side effects include bleeding or bruising, black, tarry stools, bleeding gums, blood in the urine or stools, tingling, numbness, or weakness of the lower extremities, or pinpoint red spots on the skin, among others. Likewise, the Bivalirudin treatment side effects include hypotension, backache, and nausea. Infrequent but extreme side effects include hemorrhage, coronary artery stent thrombosis, ventricular fibrillation, and renal failure.

Segment Analysis

The global heparin-induced thrombocytopenia market is segmented based on treatment drug, end-user and region.

The Argatroban Treatment Drug is Estimated to Dominate the Global Market with 32.6% market share in the forecasting period

Argatroban is approved to parenterally prevent and/or treat heparin-induced thrombocytopenia in addition to other thrombotic conditions. Argatroban also possesses anti-inflammatory and antiviral activities and has a well-established pharmacokinetics profile. The argatroban treatment drug is expected to dominate the global market owing to the new product introductions in this segment. For instance, in April 2023 Endo International plc's Par Sterile Products business started dispatching argatroban injection to healthcare suppliers via Premier's Premier ProRx private-label schedule, an insured reserve for hospitals and health systems.

Argatroban is on the FDA's elementary drugs checklist and has encountered intermittent reserve problems in the wider market. Further, the increasing need for HIT treatment is also contributing to the segmental market growth in the forecast period. For instance, in 2022, the Centers for Disease Control and Prevention publicized that there are around 900,000 individuals impacted annually in the United States with thromboembolic events. The primary threats for blood clots include older age, obesity, recent surgery or injury, family records of blood clots, cancer therapy, and other lifestyle modifications like smoking.

Geographical Penetration

North America is Estimated to hold Approximately 40.4% of the Market Share by 2030, Owing to Increased Hiparin Use and Recent Product Introduction in this Region

The increased use of heparin for distinct disorder treatments in North America is expected to boost the regional market growth during the forecast period. Heparin is typically utilized in hemodialysis and the growing number of patients receiving hemodialysis is boosting the regional market growth. For instance, in February 2022, the American Kidney Fund reported that around 570,000 Americans receive dialysis, which indicates a significant heparin usage and its adverse drug reaction, Heparin-induced thrombocytopenia (HIT).

Further, the recent market product introductions are also boosting the regional market growth during the forecast period. For instance, in June 2020, Gland Pharma Ltd. along with its associates MAIA Pharmaceuticals Inc. and Athenex Pharmaceutical Division introduced a Ready-to-Use Bivalirudin Injection in the US. This was the first on-frozen ready-to-use bivalirudin 505b (2) NDA authorized by the U.S.

COVID-19 Impact Analysis

It is estimated that COVID-19 had a positive impact on the global market as it has led to an increased usage of heparin. For instance, according to an article published in 2022 by the American Society of Hematology Journal titled ""Heparin-Induced Thrombocytopenia in COVID-19"". The infection of the SARS-CoV-2 virus elicits extreme inflammation directing to a prothrombotic condition, alluded to as COVID-related coagulopathy (CAC). CAC induces overall microvascular and macrovascular thrombosis in venous and arterial beds, leading to following multisystem organ dysfunction, and occasionally death.

The use of anticoagulants has been the cornerstone for the therapy and precluding of CAC-associated thrombotic intricacies and has been endorsed by evidence-based exercise guidelines. Owing to the commonness of multisystem organ dysfunction, heparin has appeared as the agent of preference in this scenario. While the utilization of anticoagulants is crucial, it can even direct to catastrophic complications including bleeding and heparin-induced thrombocytopenia (HIT); yet, registering of these intricacies is only lately surfacing.

By Treatment Drug
• Argatroban
• Lepirudin
• Danaparoid
• Other

By End-User
• Hospitals
• Specialty Clinics
• Academic and Research Organizations
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In April 2023, Endo International plc's Par Sterile Products business started dispatching argatroban injection to healthcare suppliers via Premier's Premier ProRx private-label schedule, an insured reserve for hospitals and health systems.
• In June 2021, Accord Healthcare acquired the United States Food and Drug Administration authorization for Argatroban in Sodium Chloride.

Competitive Landscape
The major global players in the market include Mitsubishi Tanabe Pharma, AUROMEDICS PHARMA LLC, Fresenius Kabi USA, Pfizer Inc, DAIICHI SANKYO COMPANY, LIMITED, Caplin Steriles Ltd, Hikma Pharmaceuticals PLC, NOVARTIS AG, Endo International plc, and Gland Pharma Ltd, among others.

Why Purchase the Report?
• To visualize the global heparin-induced thrombocytopenia market segmentation based on treatment drug, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of heparin-induced thrombocytopenia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The global heparin-induced thrombocytopenia market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies